Detailed analysis of all 146 Titan-family reports FDA received Oct 1–31, 2026. Every narrative was read, and each report was grouped by the main problem it describes. Tools used: Google and Claude.
The short version
- 146 reports: 141 filed by Coloplast, plus 5 forwarded by another manufacturer about Titans it didn't make.
- 127 (87%) are coded "Required Intervention"; all of those with a narrative describe a revision, replacement, repair or explant.
- Mechanical malfunctions: 93 reports (64%) (fluid loss, pump and other device failures). Median time from implant: 5 years (85 reports with an implant year). Median patient age for malfunction: 68 (42 reports with an age), range 29–85.
- Fluid loss / tubing failure was the #1 problem: 68 reports (47%). Where a break location was given, the most common one was at or near the pump (8 of the 35 breaks).
- Infection: 16 (11%). Every one with a known implant year involved a device implanted in 2025–2026.
- Sizing and placement problems: 19 (13%) — the group most tied to surgical technique. Another 6 were erosion/extrusion.
- 19 reports came from South Korea, mostly near-identical one-line "tubing leak" reports for August events — a reporting batch, not necessarily a trend.
- Only 20 of 146 reports list the device as returned to Coloplast, and no report includes an analysis result yet.
Before reading too much into the numbers
- These are counts of reports, not failure rates. MAUDE has no denominator (how many Titans are in service), so raw counts can't rank brands or months.
- This is one month of reports. Treat any pattern as provisional until it shows up across several months.
- Reporting is uneven. One overseas distributor channel sent a batch this month, and plenty of failures are never reported at all.
- One report isn't always one patient. A few reports here are the same patient or event filed more than once (see Data notes).
- "Injury" here mostly means needed surgery: of the 126 reports typed Injury, 125 are coded "Required Intervention" and 97 list "No Clinical Signs, Symptoms or Conditions" as the health effect.
- Causes are as reported — brief and second-hand, mostly relayed by Coloplast reps or distributors. No report this month contains a Coloplast evaluation finding.
- The categories below were assigned by reading each narrative alongside FDA's problem codes. They are not an FDA grouping.
1) What went wrong
One primary category per report (percentages rounded). "Pump / inflate / deflate" means no leak was reported. The fluid-loss breakdown is in section 2.
Code: Select all
CATEGORY N %
Fluid loss / tubing 68 47%
Pump / inflate / deflate 22 15%
Infection 16 11%
Malposition / migration 11 8%
Sizing 8 5%
Erosion / extrusion 6 4%
Other mechanical 3 2%
Unspecified / no detail 11 8%
Literature report 1 1%
TOTAL 146
FDA's health-effect codes flag erosion in 9 reports overall: the 6 above, plus 2 sizing reports and 1 infection report.
FDA event types: Injury 126, Malfunction 15, Other 5 (the 5 forwarded reports).
2) Fluid loss and tubing failures (68)
This is the classic failure where the device loses its saline and won't inflate. 53 of the 68 involve the tubing specifically.
- Tubing break, crack, cut or hole described: 35
- "Tubing leak" with no break described: 18
- Leak or fluid loss, site not stated: 10
- Cylinder leak or needle perforation: 3
- Reservoir leak or hole: 2
Code: Select all
WHERE THE TUBING BROKE N
At or near the pump 8
Pump-to-cylinder tubing 4
Reservoir tubing 3
Cylinder-tubing junction 2
Strain relief 1
Connector failure 1
"Left"/"right" only 2
Site not stated 14
TOTAL 35
- Timing: for tubing breaks and leaks with a known implant year (51 reports), the median was about 5 years in service. 10 were 10+ years old (oldest implanted 2007); 6 were in their first year or two.
- Early failures worth noting: three reports from Jordan, all implanted in 2026 and all failing with fluid loss by mid-September; two describe "a cut in the tube connecting the reservoir". They come from three different lots, so not one bad batch, and the reports don't say what caused the cuts. Also: a 29-year-old's 2026 implant with a break in the reservoir and cylinder tubing, and two cylinder leaks in US devices implanted in 2026.
- South Korea: all 19 reports came in through a distributor. 14 are near-identical one-liners ("removed and replaced due to a tubing leak"), 4 are infections and 1 has no narrative. 17 of the 19 events happened in August, and they reached FDA in batches between Oct 1 and Oct 29. Three more reports with the same distributor wording have no country listed.
- Country mix matters: fluid loss was 36% of US reports (32 of 89) but 73% of reports coded to other countries (30 of 41). Reporting patterns differ by country, which is another reason not to over-read raw counts.
- Other leak causes: a needle perforation of the cylinders (2019 implant), and a reservoir leak where dense scar tissue meant the old reservoir was left in place and a non-Coloplast device was implanted.
3) Pump, inflation and deflation problems — no leak reported (22)
- Pump sticky, stuck, frozen, stiff, stopped or hard to work: 7. One pump was "frozen" in a man who hadn't used his implant in 4 years (heavy scar tissue around the pump, fluid still in the system). Another sticky pump showed no defect after removal.
- Won't inflate, or only partly: 7. Includes a Titan Touch that hissed when pumped (air mixed with the fluid), a pump bulb that collapses, and a patient whose left cylinder has never fully inflated and bends sharply since surgery (hidden at first by swelling).
- Deflation problems: 5, including slow unintended deflation, failure to deflate in two devices implanted in 2026, and a 27-year-old device (implanted around 1999, a pre-Titan Mentor model) that had trouble deflating.
- Auto-inflation: 3. A reservoir replaced 3 weeks after the original surgery because of auto-inflation; a forwarded report of a Titan auto-inflating and causing pain (explanted); and a physician who has seen more auto-inflation since adopting HESO ("Hamdan extrainguinal sub-oblique", submuscular) reservoir placement, especially in muscular patients. He said it may or may not be related.
- All 6 patient-initiated reports fall in this group (each reached FDA through a manufacturer, not from the patient directly).
4) Infection (16)
- Early-phase: 12 involved devices implanted in 2026, 2 in 2025, 2 unknown. None of the known implant years was earlier than 2025.
- What happened next: 10 removed and replaced; 1 switched to a malleable; 1 got a temporary malleable spacer (Tactra), then a new inflatable several days later; 4 removed and not replaced — all 4 from South Korea.
- One infected device came from a lot with a recorded manufacturing nonconformance ("missed end of batch seal"). Coloplast states it is not related to the infection and gives no further detail.
5) Sizing, placement and erosion (25)
- Sizing (8): 3 too long/oversized — one led to extrusion, one had a "pending distal erosion", and one man found the cylinder uncomfortable and got a shorter device. 2 too short/undersized. 3 not specified.
- Malposition / migration (11): reservoir 4 (one migrated into the scrotum, two others migrated, one moved to midline); cylinders 4 (migration, two crossovers, and an SST deformity from tips not seated far enough); component not stated 1; pump 2 (high-riding; placement causing pain).
- Erosion / extrusion (6): all in devices 0–4 years old. One cylinder herniated through weakened tissue mid-shaft; one patient was switched to a Genesis malleable.
- In 3 reports the narrative itself blames the original surgery: "not placed correctly", "surgeon's original placement" with "poor dilation", and "surgeon error and potential cross over" (described as a "tricky 4+ hour case"). For two of these, Coloplast points to the placement instructions in the IFU.
- This month's literature report (UK; 473 first-time gender-affirming IPPs, 56% Coloplast) found the estimated 5-year chance of reoperation for any cause fell from about 66% for the first case to about 33% by case 473, with cumulative center experience the only independent predictor. Revision for dissatisfaction was 21.9% overall, higher with Boston Scientific than Coloplast devices. (J Sex Med 2026;23(10):qdag297)
6) How long the devices had been in
Years from implant to event, by category:
Code: Select all
CATEGORY 0-1 2-4 5-9 10+ n/a
Fluid / tubing 9 19 27 10 3
Pump/infl/defl 6 5 5 1 5
Infection 14 0 0 0 2
Malposition 4 3 3 1 0
Sizing 4 1 3 0 0
Erosion 4 2 0 0 0
Other mech. 1 0 2 0 0
Unspecified 2 0 2 2 5
Literature 0 0 0 0 1
ALL 44 30 42 14 16
Event year minus implant year. Only the year is reported, so each figure is ±1. n/a = implant year not reported.
- Infections show up in the first year or so; sizing, placement and erosion problems mostly within 4 years (18 of 25); tubing failures are spread out, mostly at 2–9 years.
- 32 reports (22%) involved devices implanted in 2026; 12 of those were infections.
- Long-lived devices in this batch: a pre-Titan Mentor device implanted around 1999 (27 years, trouble deflating), two from 2007 (about 19 years: one tubing break, one "not working"), and a 2009 Titan (about 17 years, tubing fracture near the pump).
7) Where the reports came from
- United States 89 — FL 21, NY 14, TX 9, PA 6, IL 6, OH 4, GA 4, NJ 3, CO/ID/VA 2 each, 8 other states 1 each, state missing 8. State counts aren't rates; they track where reporting surgeons practice and how many implants they do.
- South Korea 19, Australia 6, Jordan 3, Spain 2, Vietnam 2, and 1 each from Canada, Colombia, Egypt, France, Italy, Netherlands, Portugal, UK and "CI" (see Data notes). Country missing: 16.
- Who reported: health professional via a Coloplast rep 84; foreign health professional via a distributor 31; other foreign health professional 13; patients 6; health professional direct 5; literature 1; not stated 6.
- Patient age (given in 63 of 146): median 68, range 29–85. 60s: 26, 70s: 21, 50s: 11, 80s: 3, 40s: 1, 20s: 1.
8) Which Titan versions
Decoded from catalog numbers using Coloplast's Titan ordering list (for cylinder sets, the last two digits are the length in cm):
Code: Select all
TITAN SET (catalog) N
Touch pump (ES28/ES29) 52
Titan pump (ES88/ES89) 31
Touch pump, NB (EN28/EN29) 19
Titan pump, NB (EN88/EN89) 2
XL cylinders (E179..) 3
Reservoir (ER8075/ER8125) 7
Older codes (Q.., 90-9x..) 9
Other (517750/517770) 6
Not reported 17
Touch pump / Titan pump = the pump supplied with the cylinder set. NB = Narrow Base cylinders.
- Cylinder lengths (ES/EN sets): 20 cm 32, 22 cm 31, 18 cm 20, 16 cm 14, 14 cm 4, 24 cm 2, 11 cm 1. This mostly mirrors what gets implanted; it doesn't show any size failing more.
- 12 of the 19 Korean reports were Narrow Base (EN) sets.
- The older-generation codes belonged to devices implanted between 1999 and 2018 (where the year is given). The 1999 device predates the Titan name (see Data notes).
9) What Coloplast's investigations said
- 112 reports say the lot was reviewed and its devices met specification at release; nearly all add that no complaint trends, nonconformances or CAPAs were found.
- 103 say the device was not returned or received, so Coloplast says it can't comment on the device's condition.
- 20 devices are listed as returned (Sept 24–Oct 28) and 2 reports are flagged "evaluated", but no report contains an evaluation finding; results, if any, would come later as follow-up reports (10 reports already include a follow-up).
- 14 reports say no lot or history review was possible because no lot number was provided. Overall, 20 reports have no lot number on file and 17 have no catalog number.
- Exceptions: 2 lots had "several complaints" but with different failure modes, so Coloplast didn't treat them as a trend; 1 lot had the nonconformance mentioned under Infection; 2 reports where Coloplast points to the original surgical placement; and a phalloplasty patient's tubing failure that Coloplast classes as off-label use, because the labeled indication is men with ED.
- 19 reports (including the 5 forwarded ones) have no manufacturer narrative at all.
10) The 5 forwarded reports
These are voluntary reports carrying FDA's note that they arrived under 21 CFR 803.22(b)(2), the rule for a manufacturer passing along a complaint about a device it didn't make. Two refer to "non-BSC" devices, and one of those also mentions a Tactra (Boston Scientific's malleable), so the sender appears to be Boston Scientific.
- A Titan auto-inflating and causing pain; explanted.
- An infected Titan; explanted, Tactra as a temporary spacer, new inflatable several days later.
- Three near-identical reports of a patient whose "three previous" devices "did not work properly" — very likely one patient, three devices.
- All 5 show a report date of 04/30/2026 but FDA-received dates of Oct 15 and Oct 21, 2026.
11) Notable individual reports
- A 29-year-old, implanted 2026: break in the reservoir and cylinder tubing.
- Reservoir replaced for auto-inflation 3 weeks after the original surgery.
- A 125 cc reservoir would only hold 60 cc.
- Reservoir leak; dense scar tissue, so the old reservoir was left in place and a non-Coloplast implant was used.
- Small hole spotted in a reservoir while prepping it in the OR; swapped before implanting (no patient harm reported).
- Needle perforation of the cylinders (2019 implant).
- Pump "frozen" after 4 years of no use, heavy scar tissue around it.
- Physician trend report on auto-inflation with HESO placement in muscular patients.
- Titan Touch that wouldn't inflate; hissing when pumped (air mixed with the fluid).
- From a patient: left side never fully inflated and bends sharply since surgery; hasn't seen his urologist yet.
- A 27-year-old pre-Titan Mentor device (implanted around 1999) with trouble deflating.
12) Data notes (for the data-minded)
- Same event or patient filed more than once: One event was split into two reports (broken tubing in one, undersizing in the other). Two other reports look like one patient (same event date, state, age, implant year and return date; one covers the cylinders, the other the reservoir). The three "three previous devices" forwarded reports are likely one patient. The two Vietnam reports share a lot number and implant year.
- Impossible or conflicting dates: One report lists a 2020 implant for a device made in March 2021 (another report from the same lot says 2022). Another device's expiration date (Nov 2023) is before its listed 2024 implant year, so either an expired device was implanted or a date is wrong. A third says the leak came "after 10 years" but lists a 2022 implant.
- Contradictions: One report is flagged "evaluated by manufacturer" while its narrative says the device was not received. In another, the event text (from a follow-up) says explanted and replaced, but the manufacturer narrative still says "remains implanted". A third has a lot number on file, but its narrative says no lot was provided (it also had a follow-up, so the narrative may predate the lot).
- "Titan" is a family label: Coloplast names the device in these reports as the "Titan inflatable penile prosthesis family" and files them under one FDA approval (PMA P000006). That approval was first granted in July 2000 for the Mentor Alpha I; the Titan name came later. The device reported as 27 years old (implanted around 1999, with an older Mentor catalog code) is therefore a pre-Titan Mentor model, not a Titan.
- FDA's own problem codes (a report can carry several): Fluid/Blood Leak 40, Fracture 34, Adverse Event Without Identified Device or Use Problem 17, Inflation Problem 14, Insufficient Device Problem Information 9, Inadequacy of Device Shape and/or Size 8, Malposition of Device 8, Migration 6.
- Completeness: patient sex "Unknown" on 124 of 146; age missing on 83; weight, race, ethnicity and UDI blank on all 146; 13 reports have no event description at all.
- Country codes are mixed: Denmark appears as DA, Spain SP, Vietnam VM and Portugal PO (older FIPS-style codes), but South Korea is KR and the UK is GB (ISO codes). That leaves AU (Australia or Austria) and CI (Chile or Côte d'Ivoire) ambiguous; AU is most likely Australia.
- Numbering gaps: 13 numbers in Coloplast's report sequence for this month are missing from this set. They may be other products or reports not yet released; this data can't say.
- Timeliness: median 17 days from event to FDA receipt; 98 of 138 dated reports arrived within 30 days. The big outliers are a December 2022 event and a 2021 literature case. (The 30-day MDR clock starts when the manufacturer learns of an event, not on the event date.)
13) Practical takeaways
Informational only, not medical advice. Talk to your surgeon about your own situation.
- Keep your implant card (catalog and lot numbers). 20 reports had no lot number on file, and 14 manufacturer narratives say the lot review couldn't be done because no lot was provided.
- Facing a revision? Ask whether the explanted device will go back to Coloplast for analysis. Only 20 of 146 reports list the device as returned this month, and without the device Coloplast says it can't comment on its condition.
- Infections cluster early: every infection report with a known implant year involved a device implanted in 2025–2026.
- Sizing and placement problems (19 reports) are the ones most tied to surgical technique. Three narratives blame the original surgery outright, and this month's literature report (gender-affirming IPPs) found cumulative center experience to be the only independent predictor in its analysis.
- Patients can report directly to FDA through MedWatch (online, or by phone at 1-800-FDA-1088). This month only 6 of 146 reports started with a patient, and none was filed by a patient directly.
Source: FDA MAUDE, Coloplast Titan inflatable penile prosthesis family, reports received by FDA Oct 1–31, 2026. Catalog decoding per Coloplast's Titan ordering information. Counts are reports, not rates. Anyone can search MAUDE on FDA's website, and FDA's MAUDE page explains the database's limitations.
